Skip to main content

Catalyst Calendar

Scope
Catalyst

Wed, Sep 23, 2026

1 updates
RHHBY
1:15 AM

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage 1 IgAN is a...

Trial Results • Phase 3roche.com

Tue, Sep 22, 2026

1 updates
RHHBY
1:00 AM

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D...

Trial Results • Phase 2Topline results Tue, Sep 22, 2026roche.com

Thu, Sep 17, 2026

1 updates
RHHBY
1:00 AM

Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical...

Trial Results • Phase 3roche.com

Sat, Sep 12, 2026

1 updates
RHHBY
8:00 PM

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7% 1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload...

Trial Results • Phase 3Phase III trial results Sun, Sep 13, 2026roche.com

Fri, Aug 28, 2026

1 updates
RHHBY
3:00 AM

Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

The SALWEEN study showed significant improvements in vision and retinal health 1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions 1,2 By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing...

Presentation / Abstract • Phase 4APVRS presentation Fri, Aug 28, 2026roche.com